Lutetium - pluvicto and lutathera
Ended Awarded Last action
- Contract number
- 36C25025N0272
- Awardee
-
Advanced Accelerator Applications USA Inc. UEI JNM4NBNHFE66
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $2,850,695
Award facts
- Contract value 55% obligated
- $5,180,500.38 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- East Hanover, NJ 07936, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $520,814 | |
| Modification | $2,329,881 | |
| Supplemental Agreement for work within scope | $0 |
About this award
Advanced Accelerator Applications USA Inc., a Novartis subsidiary specializing in radiopharmaceutical manufacturing, was awarded a delivery order by Veterans Integrated Service Network 10 on January 1, 2025, for the supply of lutetium-based nuclear medicine products including PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) and LUTATHERA (lutetium Lu 177 dotatate). The contract carries a ceiling value of $5.18M with firm fixed pricing and an ultimate completion date of December 31, 2025. This award was issued without small business set-aside designation under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), with performance to occur at the contractor's facility in East Hanover, New Jersey. These radiopharmaceutical products are used for targeted cancer treatment and diagnostic imaging applications within the Veterans Affairs healthcare system.
This delivery order represents a continuation of Advanced Accelerator Applications USA Inc.'s significant presence in supplying specialized nuclear medicine solutions to federal healthcare agencies. The company maintains several substantial blanket purchase agreements and indefinite delivery contracts across the Department of Veterans Affairs, Defense Health Agency, and National Institutes of Health, reflecting the critical nature of these products for cancer therapy and diagnostic procedures at VA medical centers and other federal healthcare facilities. The contract vehicle streamlines procurement of these specialized radiopharmaceuticals to support the medical needs of veterans and eligible beneficiaries across the VA system.
Quick answers
Who was awarded contract 36C25025N0272?
36C25025N0272 was awarded to Advanced Accelerator Applications USA Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 1, 2025.
How much is contract 36C25025N0272 worth?
The government has obligated $2,850,695 on 36C25025N0272. Its current value, with exercised options, is $5,180,500.
Is contract 36C25025N0272 an order under another contract?
Yes. 36C25025N0272 is a delivery order under 36F79719D0169, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25025N0272 competed?
The extent of competition for 36C25025N0272 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award